The global angina pectoris drugs market size was estimated to be USD 10.17 billion in 2023 and is expected to reach USD 18.54 billion by 2034 with a CAGR of 5.61% during the forecast period 2024-2034. The market will rise as a result of factors such as the growing geriatric population, the rising incidence of cardiovascular disease, increased awareness of angina pectoris, the development of new, more effective medications, the expansion of generic drug availability, and the growing need for less invasive treatments.
More people are seeking diagnosis and treatment as angina pectoris and its symptoms become more well-known. This is partly because of educational programs and public health campaigns run by groups like the American Heart Association. For instance, AstraZeneca PLC presented favorable Phase 3 data on the ANGINA-PCI study in November 2023, proving that Brilinta effectively lowers major adverse cardiovascular events following percutaneous coronary intervention in patients with angina.
By type, the stable angina segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the increasing prevalence of chronic cardiovascular conditions, advancements in drug therapies specifically targeting stable angina, and a growing aging population that often experiences stable angina symptoms, thereby driving demand for effective and reliable pharmaceutical interventions in the management of this prevalent form of angina. For instance, Pfizer Inc. and Renovacor announced a cooperation on the research and development of new RNAi therapies for cardiovascular disorders, including angina, in October 2023. Additionally, the unstable angina segment is predicted to grow at the fastest CAGR during the forecast period owing to the heightened focus on early diagnosis and intervention, advancements in acute coronary syndrome management strategies, increasing initiatives for public awareness about the urgency of treating unstable angina, and the continuous development of innovative drugs addressing the unique challenges associated with this more critical and unpredictable form of angina.
By drugs, the beta-adrenergic blocking agent's segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the well-established efficacy of these medications in managing angina symptoms by reducing the heart's workload and oxygen demand, their widespread adoption as a first-line treatment option, the proven track record of safety and tolerability, and continuous research and development efforts enhancing the therapeutic profile of these agents. For instance, Merck & Co., Inc. received FDA clearance in December 2023 for Zepzella (asparaginase) injection to treat acute lymphoblastic leukemia. This approval might lead to an expansion of the company's product portfolio and expertise in cardiovascular medications. Additionally, the antiplatelet agent segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the crucial role these agents play in preventing blood clot formation and reducing the risk of cardiovascular events, advancements in antiplatelet drug development, rising prevalence of conditions necessitating antiplatelet therapy, and the expanding application of these agents in combination with other drugs for comprehensive cardiovascular risk management.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the convenience and patient compliance associated with oral drug administration, the widespread acceptance and familiarity of oral medications among healthcare providers and patients, and ongoing efforts by pharmaceutical companies to develop innovative and effective oral formulations for the management of angina pectoris. For instance, Novartis International AG and Verve Therapeutics entered into a strategic agreement in September 2023 to explore gene therapy candidates for the treatment of heart failure, which may have implications for the management of angina. Additionally, the transdermal segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient convenience and adherence, technological advancements in transdermal drug delivery systems, and the desire to overcome challenges associated with oral medications.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the central role of hospitals in acute and chronic cardiovascular care, the prevalence of complex cases requiring inpatient treatment, and the ready availability of specialized medical professionals capable of managing and prescribing medications for angina pectoris. For instance, Sanofi S.A.'s dedication to creating ground-breaking treatments for uncommon illnesses with potential uses in other domains, such as cardiovascular health, was demonstrated in December 2023 when the FDA approved Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder. Additionally, the homecare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on patient-centric care, advancements in technology enabling remote monitoring and telehealth solutions, and the rising preference for at-home management of chronic conditions such as angina pectoris.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a robust regulatory framework facilitating drug approvals, high awareness levels among the population regarding cardiovascular health, and the prevalence of lifestyle-related risk factors contributing to angina pectoris. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cardiovascular diseases, a growing aging population, rising awareness about heart health, improving healthcare infrastructure, and government initiatives aimed at enhancing healthcare access. For instance, the Bristol Myers Squibb Company announced good Phase 3 AMPLITUDE-O study findings in December 2023, indicating that Eliquis effectively prevents major adverse cardiovascular events in individuals with moderate-risk post-acute coronary syndrome, including those who have angina.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
More people are seeking diagnosis and treatment as angina pectoris and its symptoms become more well-known. This is partly because of educational programs and public health campaigns run by groups like the American Heart Association. For instance, AstraZeneca PLC presented favorable Phase 3 data on the ANGINA-PCI study in November 2023, proving that Brilinta effectively lowers major adverse cardiovascular events following percutaneous coronary intervention in patients with angina.
By type, the stable angina segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the increasing prevalence of chronic cardiovascular conditions, advancements in drug therapies specifically targeting stable angina, and a growing aging population that often experiences stable angina symptoms, thereby driving demand for effective and reliable pharmaceutical interventions in the management of this prevalent form of angina. For instance, Pfizer Inc. and Renovacor announced a cooperation on the research and development of new RNAi therapies for cardiovascular disorders, including angina, in October 2023. Additionally, the unstable angina segment is predicted to grow at the fastest CAGR during the forecast period owing to the heightened focus on early diagnosis and intervention, advancements in acute coronary syndrome management strategies, increasing initiatives for public awareness about the urgency of treating unstable angina, and the continuous development of innovative drugs addressing the unique challenges associated with this more critical and unpredictable form of angina.
By drugs, the beta-adrenergic blocking agent's segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the well-established efficacy of these medications in managing angina symptoms by reducing the heart's workload and oxygen demand, their widespread adoption as a first-line treatment option, the proven track record of safety and tolerability, and continuous research and development efforts enhancing the therapeutic profile of these agents. For instance, Merck & Co., Inc. received FDA clearance in December 2023 for Zepzella (asparaginase) injection to treat acute lymphoblastic leukemia. This approval might lead to an expansion of the company's product portfolio and expertise in cardiovascular medications. Additionally, the antiplatelet agent segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the crucial role these agents play in preventing blood clot formation and reducing the risk of cardiovascular events, advancements in antiplatelet drug development, rising prevalence of conditions necessitating antiplatelet therapy, and the expanding application of these agents in combination with other drugs for comprehensive cardiovascular risk management.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the convenience and patient compliance associated with oral drug administration, the widespread acceptance and familiarity of oral medications among healthcare providers and patients, and ongoing efforts by pharmaceutical companies to develop innovative and effective oral formulations for the management of angina pectoris. For instance, Novartis International AG and Verve Therapeutics entered into a strategic agreement in September 2023 to explore gene therapy candidates for the treatment of heart failure, which may have implications for the management of angina. Additionally, the transdermal segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on patient convenience and adherence, technological advancements in transdermal drug delivery systems, and the desire to overcome challenges associated with oral medications.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global angina pectoris drugs market in 2023 owing to the central role of hospitals in acute and chronic cardiovascular care, the prevalence of complex cases requiring inpatient treatment, and the ready availability of specialized medical professionals capable of managing and prescribing medications for angina pectoris. For instance, Sanofi S.A.'s dedication to creating ground-breaking treatments for uncommon illnesses with potential uses in other domains, such as cardiovascular health, was demonstrated in December 2023 when the FDA approved Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder. Additionally, the homecare segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on patient-centric care, advancements in technology enabling remote monitoring and telehealth solutions, and the rising preference for at-home management of chronic conditions such as angina pectoris.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a robust regulatory framework facilitating drug approvals, high awareness levels among the population regarding cardiovascular health, and the prevalence of lifestyle-related risk factors contributing to angina pectoris. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cardiovascular diseases, a growing aging population, rising awareness about heart health, improving healthcare infrastructure, and government initiatives aimed at enhancing healthcare access. For instance, the Bristol Myers Squibb Company announced good Phase 3 AMPLITUDE-O study findings in December 2023, indicating that Eliquis effectively prevents major adverse cardiovascular events in individuals with moderate-risk post-acute coronary syndrome, including those who have angina.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Drug, Route of Administration, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Angina Pectoris Drugs Market Report 2023 - 2034
Angina Pectoris Drugs Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Stable Angina
- Unstable Angina
- Prinz-metal’s Angina
Angina Pectoris Drugs Market Analysis & Forecast by Drugs 2023 - 2034 (Revenue USD Bn)
- Nitrates
- Antiplatelet Agents
- Beta-adrenergic Blocking Agents
- Calcium Channel Blockers
- Anti-ischemic Agents
- Statins
- Antihypertensive Agents
- Others
Angina Pectoris Drugs Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Parenteral
- Transdermal
- Others
Angina Pectoris Drugs Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Homecare
- Specialty Clinics
- Others
Angina Pectoris Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis
8. Angina Pectoris Drugs Market: Drugs Estimates & Trend Analysis
9. Angina Pectoris Drugs Market: Route of Administration Estimates & Trend Analysis
10. Angina Pectoris Drugs Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Angina Pectoris Drugs Market
13. Europe Global Angina Pectoris Drugs Market
14. Asia Pacific Global Angina Pectoris Drugs Market
15. Latin America Global Angina Pectoris Drugs Market
16. MEA Global Angina Pectoris Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Pfizer Inc.
- AstraZeneca PLC
- Merck & Co. Inc.
- Novartis International AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Johnson & Johnson
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Bayer AG
- AbbVie Inc.
- Daiichi Sankyo Company
- Limited
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 10.17 Billion |
| Forecasted Market Value ( USD | $ 18.54 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
